Utilizing Advanced Technologies to Augment Pharmacovigilance Systems: Challenges and Opportunities

被引:36
作者
Lewis, David John [1 ,2 ]
McCallum, John Fraser [3 ]
机构
[1] Novartis Pharma GmbH, Novartis Global Drug Dev, Oeflinger Str 44, D-79664 Wehr, Germany
[2] Univ Hertfordshire, Dept Pharm Pharmacol & Postgrad Med, Hatfield AL10 9AB, Herts, England
[3] Roche Prod Ltd, Prod Dev Safety Risk Management, 6 Falcon Way,Shire Pk, Welwyn Garden City AL7 1TW, Herts, England
关键词
Pharmacovigilance; Information technology; Emerging technology; Artificial intelligence; Automation; ARTIFICIAL-INTELLIGENCE; SOCIAL MEDIA; BIG DATA; MEDICINE;
D O I
10.1007/s43441-019-00023-3
中图分类号
R-058 [];
学科分类号
摘要
There are significant challenges and opportunities in deploying and utilizing advanced information technology (IT) within pharmacovigilance (PV) systems and across the pharmaceutical industry. Various aspects of PV will benefit from automation (e.g., by improving standardization or increasing data quality). Several themes are developed, highlighting the challenges faced, exploring solutions, and assessing the potential for further research. Automation of the workflow for processing of individual case safety reports (ICSRs) is adopted as a use case. This involves a logical progression through a series of steps that when linked together comprise the complete work process required for the effective management of ICSRs. We recognize that the rapid development of new technologies will invariably outpace the regulations applicable to PV systems. Nevertheless, we believe that such systems may be improved by intelligent automation. It is incumbent on the owners of these systems to explore opportunities presented by new technologies with regulators in order to evaluate the applicability, design, deployment, performance, validation and maintenance of advanced technologies to ensure that the PV system continues to be fit for purpose. Proposed approaches to the validation of automated PV systems are presented. A series of definitions and a critical appraisal of important considerations are provided in the form of use cases. We summarize progress made and opportunities for the development of automation of future systems. The overall goal of automation is to provide high quality safety data in the correct format, in context, more quickly, and with less manual effort. This will improve the evidence available for scientific assessment and helps to inform and expedite decisions about the minimization of risks associated with medicines.
引用
收藏
页码:888 / 899
页数:12
相关论文
共 50 条
[1]  
[Anonymous], 2008, COMM DEC 28 4 2008 A
[2]  
[Anonymous], 1950, Mind
[3]  
[Anonymous], 2019, INT J RHEUM DIS
[4]  
[Anonymous], 2013, NIPS
[5]  
[Anonymous], 2017, J BIOMEDICAL SEMANTI, V8, P1
[6]  
[Anonymous], VENTURE BEAT
[7]  
[Anonymous], 2010, MINIMUM REQUIREMENTS
[8]  
[Anonymous], GUID GOOD PHARM PRAC
[9]   A Bayesian neural network method for adverse drug reaction signal generation [J].
Bate, A ;
Lindquist, M ;
Edwards, IR ;
Olsson, S ;
Orre, R ;
Lansner, A ;
De Freitas, RM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (04) :315-321
[10]   Translating Artificial Intelligence Into Clinical Care [J].
Beam, Andrew L. ;
Kohane, Isaac S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (22) :2368-2369